相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer
G. Middleton et al.
ANNALS OF ONCOLOGY (2022)
An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?
Nathan Cherny
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Superforecasting reality check: Evidence from a small pool of experts and expedited identification
Ilias Katsagounos et al.
EUROPEAN JOURNAL OF OPERATIONAL RESEARCH (2021)
Improving target assessment in biomedical research: the GOT-IT recommendations
Christoph H. Emmerich et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Open Targets Platform: supporting systematic drug-target identification and prioritisation
David Ochoa et al.
NUCLEIC ACIDS RESEARCH (2021)
Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation
Kurinchi S. Gurusamy et al.
PEERJ (2021)
Bias, Information, Noise: The BIN Model of Forecasting
Ville A. Satopaa et al.
MANAGEMENT SCIENCE (2021)
Self-organization in cancer: Implications for histopathology, cancer cell biology, and metastasis
Senthil K. Muthuswamy
CANCER CELL (2021)
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data
Andreas Bender et al.
DRUG DISCOVERY TODAY (2021)
Cancer evolution: Darwin and beyond
Roberto Vendramin et al.
EMBO JOURNAL (2021)
Capturing cancer evolution using genetically engineered mouse models (GEMMs)
William Hill et al.
TRENDS IN CELL BIOLOGY (2021)
Reviving an R&D pipeline: a step change in the Phase II success rate
Shuang S. Wu et al.
DRUG DISCOVERY TODAY (2021)
Patient-derived xenograft models-the future of personalised cancer treatment
Jenna Bhimani et al.
BRITISH JOURNAL OF CANCER (2020)
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
Riyaz Shah et al.
CLINICAL LUNG CANCER (2020)
Our best weapons against cancer are not magic bullets
Vinay Prasad
NATURE (2020)
2019 biotech IPOs: party on
Chris Morrison
NATURE REVIEWS DRUG DISCOVERY (2020)
Management of acute ischemic stroke
Michael S. Phipps et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia
Andrew D. Krystal et al.
NATURE MEDICINE (2020)
FROM THE ANALYST'S COUCH Breaking Eroom's Law
Michael S. Ringel et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery
Jason E. Ekert et al.
SLAS DISCOVERY (2020)
Cell Death in the Origin and Treatment of Cancer
Andreas Strasser et al.
MOLECULAR CELL (2020)
Excitotoxicity: Still Hammering the Ischemic Brain in 2020
Dennis W. Choi
FRONTIERS IN NEUROSCIENCE (2020)
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet
Andreas Bender et al.
DRUG DISCOVERY TODAY (2020)
A metastasis map of human cancer cell lines
Xin Jin et al.
NATURE (2020)
Small-molecule inhibitors of human mitochondrial DNA transcription
Nina A. Bonekamp et al.
NATURE (2020)
The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and Progress
Margaret C. Grabb et al.
PHARMACEUTICAL MEDICINE (2020)
Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications
Kristin Fabre et al.
LAB ON A CHIP (2020)
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
Andreas R. Baudy et al.
LAB ON A CHIP (2020)
Are Ideas Getting Harder to Find?
Nicholas Bloom et al.
AMERICAN ECONOMIC REVIEW (2020)
Estimation of clinical trial success rates and related parameters
Chi Heem Wong et al.
BIOSTATISTICS (2019)
The PRISM project: Social withdrawal from an RDoC perspective
Bruce N. Cuthbert
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2019)
One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry
Etienne Billette de Villemeur et al.
JOURNAL OF HEALTH ECONOMICS (2019)
The Potential Use of Metabolic Cofactors in Treatment of NAFLD
Adil Mardinoglu et al.
NUTRIENTS (2019)
Heterogenising study samples across testing time improves reproducibility of behavioural data
Carina Bodden et al.
SCIENTIFIC REPORTS (2019)
Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development
Volker Lohmann
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2019)
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development
Andrew D. Krystal et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Improving the odds of drug development success through human genomics: modelling study
Aroon D. Hingorani et al.
SCIENTIFIC REPORTS (2019)
Modelling cancer in microfluidic human organs-on-chips
Alexandra Sontheimer-Phelps et al.
NATURE REVIEWS CANCER (2019)
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
Bernardo Ribeiro da Cunha et al.
ANTIBIOTICS-BASEL (2019)
Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
Gabriel Helmlinger et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Machine learning-powered antibiotics phenotypic drug discovery
Sannah Zoffmann et al.
SCIENTIFIC REPORTS (2019)
Hans Christian Andersen and the Value of New Cancer Treatments
Richard L. Schilsky et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
PREPARE: guidelines for planning animal research and testing
Adrian J. Smith et al.
LABORATORY ANIMALS (2018)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Hsin-Pei Shih et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Hans Christian Andersen and the Value of New Cancer Treatments
Richard L. Schilsky et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines
Thomas J. Hwang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Paul Morgan et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions
Sabine U. Vorrink et al.
TOXICOLOGICAL SCIENCES (2018)
The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
Jaeyun Jung et al.
CANCER RESEARCH AND TREATMENT (2018)
Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment?
Susanne Wieschowski et al.
PLOS BIOLOGY (2018)
Reproducibility of preclinical animal research improves with heterogeneity of study samples
Bernhard Voelkl et al.
PLOS BIOLOGY (2018)
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
John Marquart et al.
JAMA ONCOLOGY (2018)
The UK Biobank resource with deep phenotyping and genomic data
Clare Bycroft et al.
NATURE (2018)
Boom: 2018's biotech IPOs
Chris Morrison
NATURE REVIEWS DRUG DISCOVERY (2018)
Burgeoning oncology pipeline raises questions about sustainability
Jon Moser et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
User's guide to correlation coefficients
Haldun Akoglu
TURKISH JOURNAL OF EMERGENCY MEDICINE (2018)
Genetically engineered mouse models in oncology research and cancer medicine
Kelly Kersten et al.
EMBO MOLECULAR MEDICINE (2017)
Translatability score revisited: differentiation for distinct disease areas
Alexandra Wendler et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Systematic heterogenization for better reproducibility in animal experimentation
S. Helene Richter
LAB ANIMAL (2017)
Patient-derived xenografts undergo mouse-specific tumor evolution
Uri Ben-David et al.
NATURE GENETICS (2017)
Approvals in 2016: questioning the clinical benefit of anticancer therapies
Christopher M. Booth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Implications of cancer evolution for drug development
Samra Turajlic et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The druggable genome and support for target identification and validation in drug development
Chris Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform
Aleksander Skardal et al.
SCIENTIFIC REPORTS (2017)
Enhancing reproducibility: Failures from Reproducibility Initiatives underline core challenges
Kevin Mullane et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
William R. Proctor et al.
ARCHIVES OF TOXICOLOGY (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions
Christopher A. Lipinski
ADVANCED DRUG DELIVERY REVIEWS (2016)
Guidelines to improve animal study design and reproducibility for Alzheimer's disease and related dementias: For funders and researchers
Heather M. Snyder et al.
ALZHEIMERS & DEMENTIA (2016)
Predicting Insulin Treatment Scenarios with the Net Effect Method: Domain of Validity
Martina Vettoretti et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2016)
2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph
Nicholas A. Meanwell
JOURNAL OF MEDICINAL CHEMISTRY (2016)
NCI-60 Cell Line Screening: A Radical Departure in Its Time
Bruce A. Chabner
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
The Prognostic Impact of Tumor Volume in Patients with Clinical Stage IA Non-Small Cell Lung Cancer
Tomoyoshi Takenaka et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Consistency in large pharmacogenomic studies
Paul Geeleher et al.
NATURE (2016)
Reproducible pharmacogenomic profiling of cancer cell line panels
Peter M. Haverty et al.
NATURE (2016)
Antibacterial drug discovery in the resistance era
Eric D. Brown et al.
NATURE (2016)
Screening out irrelevant cell-based models of disease
Peter Horvath et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Limits to Personalized Cancer Medicine
Ian F. Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Disciplined approach to drug discovery and early development
Robert M. Plenge
SCIENCE TRANSLATIONAL MEDICINE (2016)
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis
Cyrille Orset et al.
STROKE (2016)
NCI-60 Cell Line Screening: A Radical Departure in Its Time
Bruce A. Chabner
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Jack W. Scannell et al.
PLOS ONE (2016)
The Researchers' View of Scientific Rigor-Survey on the Conduct and Reporting of In Vivo Research
Thomas S. Reichlin et al.
PLOS ONE (2016)
A Model Qualification Method for Mechanistic Physiological QSP Models to Support Model-Informed Drug Development
C. M. Friedrich
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Unconventional screening approaches for antibiotic discovery
Maya A. Farha et al.
ANTIMICROBIAL THERAPEUTICS REVIEWS (2015)
Minireview: Were the IGF Signaling Inhibitors All Bad?
Heather Beckwith et al.
MOLECULAR ENDOCRINOLOGY (2015)
RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration
Diego Peretti et al.
NATURE (2015)
The support of human genetic evidence for approved drug indications
Matthew R. Nelson et al.
NATURE GENETICS (2015)
Why is it hard to terminate failing projects in pharmaceutical R&D?
Richard W. Peck et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Preclinical target validation using patient-derived cells
Aled M. Edwards et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
ESKAPEing the labyrinth of antibacterial discovery
Ruben Tommasi et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
The Economics of Reproducibility in Preclinical Research
Leonard P. Freedman et al.
PLOS BIOLOGY (2015)
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Peter Eirew et al.
NATURE (2015)
Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNA Synthetase via High-Throughput Orthogonal Screening
Laura Pedro-Rosa et al.
JOURNAL OF BIOMOLECULAR SCREENING (2015)
Identifying and Cultivating Superforecasters as a Method of Improving Probabilistic Predictions
Barbara Mellers et al.
PERSPECTIVES ON PSYCHOLOGICAL SCIENCE (2015)
Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo
John A. Hickman et al.
BIOTECHNOLOGY JOURNAL (2014)
SYRCLE's risk of bias tool for animal studies
Carlijn R. Hooijmans et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically
Emily S. Sena et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2014)
On the History of Hepatitis C Virus Cell Culture Systems
Volker Lohmann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Trends and Exceptions of Physical Properties on Antibacterial Activity for Gram-Positive and Gram-Negative Pathogens
Dean G. Brown et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Recent Progress on the Development of Novel Antitubercular Agents from Whole-Cell Screening Hits
Fumiaki Yokokawa
JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN (2014)
The International Serious Adverse Events Consortium
Arthur L. Holden et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The discovery of first-in-class drugs: origins and evolution
Joerg Eder et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Bringing rigour to translational medicine
David W. Howells et al.
NATURE REVIEWS NEUROLOGY (2014)
Curing Chronic Hepatitis C - The Arc of a Medical Triumph
Raymond T. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Therapy for Hepatitis C - The Costs of Success
Jay H. Hoofnagle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Comparison of Protein Kinases Inhibitor Screening Methods Using Both Enzymatic Activity and Binding Affinity Determination
Amalie Frederikke Rudolf et al.
PLOS ONE (2014)
Use (and abuse) of expert elicitation in support of decision making for public policy
M. Granger Morgan
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
An investigation of the false discovery rate and the misinterpretation of p-values
David Colquhoun
ROYAL SOCIETY OPEN SCIENCE (2014)
Toward the future of psychiatric diagnosis: the seven pillars of RDoC
Bruce N. Cuthbert et al.
BMC MEDICINE (2013)
The decline and fall of the IGF-I receptor
Renato Baserga
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Questions about DISC1 as a genetic risk factor for schizophrenia
P. F. Sullivan
MOLECULAR PSYCHIATRY (2013)
Inconsistency in large pharmacogenomic studies
Benjamin Haibe-Kains et al.
NATURE (2013)
The most transformative drugs of the past 25 years: a survey of physicians
Aaron S. Kesselheim et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Chemical predictive modelling to improve compound quality
John G. Cumming et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Platforms for antibiotic discovery
Kim Lewis
NATURE REVIEWS DRUG DISCOVERY (2013)
Validating therapeutic targets through human genetics
Robert M. Plenge et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research
Paul A. Lapchak et al.
TRANSLATIONAL STROKE RESEARCH (2013)
THE INNOVATIVE MEDICINES INITIATIVE: A PUBLIC PRIVATE PARTNERSHIP MODEL TO FOSTER DRUG DISCOVERY
Elisabetta Vaudano
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2013)
Predictive probability of success in clinical drug development
Mauro Gasparini et al.
EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH (2013)
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
Paul Morgan et al.
DRUG DISCOVERY TODAY (2012)
Translatability scoring in drug development: eight case studies
Alexandra Wendler et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
A call for transparent reporting to optimize the predictive value of preclinical research
Story C. Landis et al.
NATURE (2012)
Raise standards for preclinical cancer research
C. Glenn Begley et al.
NATURE (2012)
Quantifying the chemical beauty of drugs
G. Richard Bickerton et al.
NATURE CHEMISTRY (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines
Carlijn R. Hooijmans et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Challenges of Antibacterial Discovery
Lynn L. Silver
CLINICAL MICROBIOLOGY REVIEWS (2011)
How were new medicines discovered?
David C. Swinney et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Believe it or not: how much can we rely on published data on potential drug targets?
Florian Prinz et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Evaluating Preclinical Efficacy
Mark A. Atkinson
SCIENCE TRANSLATIONAL MEDICINE (2011)
Breaking Free of Sample Size Dogma to Perform Innovative Translational Research
Peter Bacchetti et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Human cancers express mutator phenotypes: origin, consequences and targeting
Lawrence A. Loeb
NATURE REVIEWS CANCER (2011)
Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression
Catherine Belzung et al.
BIOLOGY OF MOOD & ANXIETY DISORDERS (2011)
Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders
Thomas Insel et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
Rocio Sotillo et al.
NATURE (2010)
A route to more tractable expert advice
Willy Aspinall
NATURE (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Carol Kilkenny et al.
PLOS BIOLOGY (2010)
Novel trends in high-throughput screening
Lorenz M. Mayr et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence β-lactams)
Ronald Bentley
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY (2009)
Hepatitis C virus replicons: dinosaurs still in business?
I. Woerz et al.
JOURNAL OF VIRAL HEPATITIS (2009)
Shifting paradigms: the seeds of oncogene addiction
Charles L. Sawyers
NATURE MEDICINE (2009)
OPINION Assessing the translatability of drug projects: what needs to be scored to predict success?
Martin Wehling
NATURE REVIEWS DRUG DISCOVERY (2009)
Lessons from 60 years of pharmaceutical innovation
Bernard Munos
NATURE REVIEWS DRUG DISCOVERY (2009)
Good Laboratory Practice Preventing Introduction of Bias at the Bench
Malcolm R. Macleod et al.
STROKE (2009)
The FDA critical path initiative and its influence on new drug development
Janet Woodcock et al.
ANNUAL REVIEW OF MEDICINE (2008)
Simple, Defensible Sample Sizes Based on Cost Efficiency
Peter Bacchetti et al.
BIOMETRICS (2008)
Is bigger better for depression trials?
Kenneth S. Liu et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2008)
A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients
Marie-Aimee Dronne et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2008)
Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality
Malcolm R. Macleod et al.
STROKE (2008)
Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke
Emily Sena et al.
STROKE (2007)
Comparison of treatment effects between animal experiments and clinical trials: systematic review
Pablo Perel et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
Drugs for bad bugs: confronting the challenges of antibacterial discovery
David J. Payne et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Strategies to optimize the validity of disease models in the drug discovery process
F Sams-Dodd
DRUG DISCOVERY TODAY (2006)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
An introduction to ROC analysis
Tom Fawcett
PATTERN RECOGNITION LETTERS (2006)
Assurance in clinical trial design
A O'Hagan et al.
PHARMACEUTICAL STATISTICS (2005)
The value of information and optimal clinical trial design
AR Willan et al.
STATISTICS IN MEDICINE (2005)
Timeline - Chemotherapy and the war on cancer
BA Chabner et al.
NATURE REVIEWS CANCER (2005)
Navigating chemical space for biology and medicine
C Lipinski et al.
NATURE (2004)
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
G Morgan et al.
CLINICAL ONCOLOGY (2004)
Designing screens: How to make your hits a hit
WP Walters et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Modern biomedical research: an internally self-consistent universe with little contact with medical reality?
DF Horrobin
NATURE REVIEWS DRUG DISCOVERY (2003)
Hepatitis C virus replicons: potential role for drug development
R Bartenschlager
NATURE REVIEWS DRUG DISCOVERY (2002)
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
LK Shawver et al.
CANCER CELL (2002)
Creating a structural genomics consortium
AR Williamson
NATURE STRUCTURAL BIOLOGY (2000)
分享论文
